. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Brain Behav Immun. 2012 Sep 23;28:16–24. doi: 10.1016/j.bbi.2012.09.004

Table 4.

Estimated change in outcomes (4 months minus baseline) by intervention group, adjusted for baseline outcome levels.

Outcome	Placebo	1.25 g/day n-3	2.5 g/day n-3	P-values for group comparisons^*
Outcome	Placebo	1.25 g/day n-3	2.5 g/day n-3	Low Dose vs Placebo	High Dose vs Placebo	High vs Low Dose
Change in Telomere length	−43 (−131, 46)	21 (−57, 99)	50 (−33, 133)	0.53	0.29	0.87
Change in ln(Telomerase)	0.066 (−0.11, 0.24)	0.10 (−0.045, 0.25)	0.040 (−0.12, 0.20)	0.94	0.97	0.83
Change in ln(F2-isoprostanes)	0.073 (−0.021, 0.17)	−0.094 (−0.17, −0.014)	−0.086 (−0.17, 0.0009)	0.02	0.04	0.99

Units: Telomere length = base pairs; Telomerase = activity/10000 cells; F2-isoprostanes = ng/ml

Numbers in parentheses are 95% confidence intervals.

Tukey-Kramer adjustment for multiple comparisons

Sample sizes: Telomerase, n=94; Telomere length, n=106; F2-isoprostanes, n=97